{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:26:20Z","timestamp":1761845180458,"version":"build-2065373602"},"reference-count":44,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011234","name":"Bio-Rad Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011234","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008021","name":"Bristol-Myers Squibb Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jmdjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Molecular Diagnostics"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.jmoldx.2020.02.011","type":"journal-article","created":{"date-parts":[[2020,3,21]],"date-time":"2020-03-21T03:13:37Z","timestamp":1584760417000},"page":"736-747","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["External Quality Assessment Schemes for Biomarker Testing in Oncology"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6339-9771","authenticated-orcid":false,"given":"Kaat","family":"Van Casteren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4498-8386","authenticated-orcid":false,"given":"Cleo","family":"Keppens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3655-143X","authenticated-orcid":false,"given":"Ed","family":"Schuuring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zandra C.","family":"Deans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Normanno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3260-6790","authenticated-orcid":false,"given":"Simon J.","family":"Patton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth M.C.","family":"Dequeker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmoldx.2020.02.011_bib1","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2017.76.7293","volume":"36","author":"Kalemkerian","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib2","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1200\/JCO.2016.71.9807","article-title":"Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology","volume":"35","author":"Sepulveda","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib3","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.1158\/1078-0432.CCR-09-0888","article-title":"Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials","volume":"15","author":"Jackman","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib4","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/jnci\/dji112","article-title":"Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer","volume":"97","author":"Cappuzzo","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib5","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1177\/1758834017719829","article-title":"Treating KRAS-mutant NSCLC: latest evidence and clinical consequences","volume":"9","author":"Garrido","year":"2017","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib6","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1634\/theoncologist.2016-0458","article-title":"Targeting BRAF-mutant non-small cell lung cancer: from molecular profiling to rationally designed therapy","volume":"22","author":"Baik","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.lungcan.2015.11.004","article-title":"Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer","volume":"92","author":"Hames","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib8","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.lungcan.2009.11.020","article-title":"KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies","volume":"69","author":"Mao","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib9","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S1470-2045(08)70206-7","article-title":"Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer","volume":"9","author":"Linardou","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib10","first-page":"314","article-title":"Extended RAS testing in metastatic colorectal cancer-refining the predictive molecular biomarkers","volume":"6","author":"Al-Shamsi","year":"2015","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib11","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00428-015-1876-7","article-title":"RAS testing in metastatic colorectal cancer: advances in Europe","volume":"468","author":"Van Krieken","year":"2016","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib12","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/ajcp\/aqw209","article-title":"Molecular biomarkers for the evaluation of colorectal cancer","volume":"147","author":"Sepulveda","year":"2017","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1200\/JCO.2015.63.9674","article-title":"Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology provisional clinical opinion update 2015","volume":"34","author":"Allegra","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib14","doi-asserted-by":"crossref","first-page":"iv267","DOI":"10.1093\/annonc\/mdy320","article-title":"Euracan: gastrointestinal stromal tumours: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Casali","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib15","doi-asserted-by":"crossref","first-page":"v126","DOI":"10.1093\/annonc\/mdv297","article-title":"Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26 Suppl 5","author":"Dummer","year":"2015","journal-title":"Ann Oncol"},{"year":"2012","series-title":"ISO 15189:2012 Medical Laboratories\u2014Particular Requirements for Quality and Competence","key":"10.1016\/j.jmoldx.2020.02.011_bib16"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib17","doi-asserted-by":"crossref","first-page":"20524","DOI":"10.18632\/oncotarget.24980","article-title":"A stitch in time saves nine: external quality assessment rounds demonstrate improved quality of biomarker analysis in lung cancer","volume":"9","author":"Keppens","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib18","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1634\/theoncologist.2014-0382","article-title":"External quality assessment unravels interlaboratory differences in quality of RAS testing for anti-EGFR therapy in colorectal cancer","volume":"20","author":"Tack","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib19","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1373\/clinchem.2014.222679","article-title":"Circulating tumor DNA as a liquid biopsy for cancer","volume":"61","author":"Heitzer","year":"2015","journal-title":"Clin Chem"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib20","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2012.45.2011","article-title":"Liquid biopsies: genotyping circulating tumor DNA","volume":"32","author":"Diaz","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib21","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.2147\/OTT.S100901","article-title":"Cell-free DNA as a diagnostic marker for cancer: current insights","volume":"9","author":"Salvi","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib22","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrclinonc.2017.14","article-title":"Integrating liquid biopsies into the management of cancer","volume":"14","author":"Siravegna","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib23","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","article-title":"Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review","volume":"36","author":"Merker","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib24","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.jtho.2018.05.030","article-title":"Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC","volume":"13","author":"Rolfo","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib25","doi-asserted-by":"crossref","first-page":"420","DOI":"10.21037\/tlcr.2016.08.06","article-title":"Pros: can tissue biopsy be replaced by liquid biopsy?","volume":"5","author":"Ilie","year":"2016","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib26","doi-asserted-by":"crossref","first-page":"46","DOI":"10.21037\/atm.2017.01.32","article-title":"The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer?","volume":"5","author":"Kwapisz","year":"2017","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib27","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1136\/jclinpath-2014-202404","article-title":"Guidance for laboratories performing molecular pathology for cancer patients","volume":"67","author":"Cree","year":"2014","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib28","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00428-017-2222-z","article-title":"Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective from an EQA providers' survey","volume":"471","author":"Deans","year":"2017","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib29","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1634\/theoncologist.2017-0425","article-title":"FDA benefit-risk assessment of osimertinib for the treatment of metastatic non-small cell lung cancer harboring epidermal growth factor receptor T790M mutation","volume":"23","author":"Odogwu","year":"2018","journal-title":"Oncologist"},{"year":"2016","series-title":"FDA Approves First Blood Test to Detect Gene Mutation Associated with Non-Small Cell Lung Cancer","key":"10.1016\/j.jmoldx.2020.02.011_bib30"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib31","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jmoldx.2018.03.006","article-title":"Detection of EGFR variants in plasma: a multilaboratory comparison of a real-time PCR EGFR mutation test in Europe","volume":"20","author":"Keppens","year":"2018","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib32","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jtho.2017.04.003","article-title":"Plasma ctDNA analysis for detection of the EGFR T790M mutation in patients with advanced non-small cell lung cancer","volume":"12","author":"Jenkins","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib33","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1186\/s12885-018-4694-x","article-title":"International pilot external quality assessment scheme for analysis and reporting of circulating tumour DNA","volume":"18","author":"Keppens","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib34","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00428-017-2226-8","article-title":"EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial","volume":"471","author":"Fassunke","year":"2017","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib35","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41416-018-0204-9","article-title":"Accreditation, setting and experience as indicators to assure quality in oncology biomarker testing laboratories","volume":"119","author":"Tack","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib36","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jmoldx.2015.09.004","article-title":"Three rounds of external quality assessment in France to evaluate the performance of 28 platforms for multiparametric molecular testing in metastatic colorectal and non-small cell lung cancer","volume":"18","author":"Dequeker","year":"2016","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00428-012-1354-4","article-title":"Guideline on the requirements of external quality assessment programs in molecular pathology","volume":"462","author":"van Krieken","year":"2013","journal-title":"Virchows Arch"},{"year":"2010","series-title":"ISO 17043:2010 Medical Laboratories\u2014Conformity Assessment\u2014General Requirements for Proficiency Testing","key":"10.1016\/j.jmoldx.2020.02.011_bib38"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib39","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12943-018-0789-x","article-title":"KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target","volume":"17","author":"Roman","year":"2018","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib40","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13046-018-0719-1","article-title":"Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities","volume":"37","author":"Porru","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib41","doi-asserted-by":"crossref","first-page":"10259","DOI":"10.18632\/oncotarget.21982","article-title":"Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors","volume":"9","author":"Mehrotra","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib42","doi-asserted-by":"crossref","first-page":"7808","DOI":"10.1158\/1078-0432.CCR-11-1712","article-title":"Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas","volume":"17","author":"Taniguchi","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib43","doi-asserted-by":"crossref","first-page":"21122","DOI":"10.18632\/oncotarget.24950","article-title":"Cross-platform comparison for the detection of RAS mutations in cfDNA (ddPCR Bio-Rad detection assay, BEAMing assay, and NGS strategy)","volume":"9","author":"Garcia","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jmoldx.2020.02.011_bib44","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00428-019-02571-3","article-title":"IQN path ASBL white paper from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing","volume":"474","author":"Deans","year":"2019","journal-title":"Virchows Arch"}],"container-title":["The Journal of Molecular Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157820300581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157820300581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:13:14Z","timestamp":1761502394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525157820300581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S1525157820300581"],"URL":"https:\/\/doi.org\/10.1016\/j.jmoldx.2020.02.011","relation":{},"ISSN":["1525-1578"],"issn-type":[{"type":"print","value":"1525-1578"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"External Quality Assessment Schemes for Biomarker Testing in Oncology","name":"articletitle","label":"Article Title"},{"value":"The Journal of Molecular Diagnostics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmoldx.2020.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}